Aquestive Therapeutics Faces FDA Deficiencies for Anaphylm Drug Application, Class Action Lawsuit Filed

Key Takeaways

• FDA has identified deficiencies in Aquestive Therapeutics’ New Drug Application for Anaphylm that prevent labeling discussions and post-marketing commitments
• Class action lawsuit filed against Aquestive alleging the company misled investors about likelihood of meeting January 31, 2026 PDUFA approval date
• Company must resolve all FDA deficiencies before any approval can be granted, creating uncertainty around Anaphylm’s commercial timeline

---

Aquestive Therapeutics, Inc. (NASDAQ: AQST) is facing significant regulatory and legal challenges as the FDA has identified deficiencies in the company’s New Drug Application (NDA) for Anaphylm, its investigational anaphylaxis treatment, according to a class action complaint filed by Robbins LLP.

FDA Raises Concerns About Anaphylm Application

The FDA’s identification of deficiencies in Aquestive’s NDA represents a significant setback for the biotechnology company. These deficiencies are substantial enough to preclude standard regulatory discussions about drug labeling and post-marketing commitments—critical steps in the approval process that typically occur when the FDA is preparing to approve a medication.

Under FDA regulations, all identified deficiencies must be adequately addressed and resolved before any New Drug Application can receive approval. This requirement creates substantial uncertainty around whether Aquestive can meet its target Prescription Drug User Fee Act (PDUFA) date of January 31, 2026.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for anaphylaxis treatment, with Anaphylm most exposed to upcoming decisions. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Class Action Lawsuit Alleges Investor Deception

Robbins LLP has initiated a class action lawsuit against Aquestive Therapeutics, alleging that company executives misled investors about the likelihood of regulatory approval. According to the complaint, defendants “created the false impression that Aquestive was on track to receive approval” for Anaphylm by the January 2026 PDUFA date.

The lawsuit suggests that company leadership may have been aware of potential regulatory hurdles while publicly maintaining optimistic timelines for approval. Such allegations, if proven, could result in significant financial penalties and damage to the company’s reputation.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Competitive Landscape

Anaphylm represents Aquestive’s attempt to enter the substantial anaphylaxis treatment market, currently dominated by established products like EpiPen and Auvi-Q. The company has been developing Anaphylm as an alternative epinephrine delivery system for patients at risk of severe allergic reactions.

The regulatory setback comes at a critical time for Aquestive, as investors and patients have been anticipating new treatment options in the anaphylaxis space. The company’s stock performance and future funding capabilities may be significantly impacted by both the FDA’s concerns and the ongoing legal proceedings.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for anaphylaxis treatment pricing, access, and launch sequencing.

Regulatory Path Forward Remains Uncertain

For Aquestive to move forward with Anaphylm, the company must first comprehensively address each deficiency identified by the FDA. This process typically involves submitting additional data, conducting further studies, or modifying the drug’s formulation or delivery mechanism.

The timeline for resolving FDA deficiencies varies significantly depending on their nature and complexity. Some issues can be addressed through additional documentation or minor modifications, while others may require extensive additional clinical trials or fundamental changes to the product.

Industry observers note that while FDA deficiency letters represent serious obstacles, they do not necessarily preclude eventual approval if companies can adequately address the agency’s concerns. However, the process often extends development timelines and increases costs substantially.

IntelligenceStrategic Takeaways▾

FDA has identified deficiencies in Aquestive Therapeutics’ New Drug Application for Anaphylm that prevent labeling discussions and post-marketing commitments Class action lawsuit filed against Aquestive alleging the company misled investors about likelihood of meeting January 31, 2026 PDUFA approval date Company must resolve all FDA deficiencies before any approval can be granted, creating uncertainty around Anaphylm’s commercial timeline

Implications for Stakeholders

The current situation creates uncertainty for multiple stakeholder groups. Investors face potential losses and extended timelines before any potential return on investment. Patients awaiting new anaphylaxis treatment options may experience delays in accessing Anaphylm if it eventually receives approval.

For Aquestive Therapeutics, the company must now navigate both regulatory challenges and legal proceedings while maintaining its broader development pipeline and business operations.

---

Frequently Asked Questions

What does this mean for patients waiting for Anaphylm?

Patients will likely face significant delays in accessing Anaphylm, as the company must first resolve FDA deficiencies before approval can be granted. The original January 2026 timeline is now uncertain.

When will Anaphylm be available if approved?

The timeline is now uncertain due to FDA deficiencies that must be resolved. The original PDUFA date of January 31, 2026 is unlikely to be met, and no new timeline has been established.

How does this compare to existing anaphylaxis treatments?

Anaphylm was being developed as an alternative to existing epinephrine auto-injectors like EpiPen and Auvi-Q. However, until FDA deficiencies are resolved, patients must continue relying on currently approved treatments.

Related coverage

• FDA Approves Vertex’s First-in-Class Non-Opioid Pain Drug Journavx
• Nektar Therapeutics pipeline update: REZPEG, amphotericin B and UK site changes
• FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain